Key result
Discontinuation of ACEi/ARB in patients with advanced CKD significantly increased eGFR from 16.38 to 26.6 ml/min/1.73 m2 at 12 months (p=0.0001), delaying the onset of renal replacement therapy.
Why the study?
Does discontinuation of ACEi/ARB improve eGFR in patients with advanced chronic kidney disease nearing renal replacement therapy?
Population
52 patients with advanced chronic kidney disease attending a low clearance clinic in preparation for renal…
Comparison
Discontinuation of angiotensin converting enzyme… vs The same patients' trajectory in the 12 months…
Design
Cohort
Follow-up
at least 12 months before and after discontinuation
Authors
Loading...
ACEi/ARB discontinuation may improve eGFR in advanced CKD; hypothesis-generating and requires RCTs before practice change.
Observational (n=52)
No
Does discontinuation of ACEi/ARB improve eGFR in patients with advanced chronic kidney disease nearing renal replacement therapy?
Absolute Event Rate: 26.6% vs 16.38%
p-value: p=0.0001
Discontinuation of ACEi/ARB in patients with advanced CKD significantly improved eGFR and reversed its decline, potentially delaying the need for renal replacement therapy.
Ahmed et al. (2009) conducted an observational in Advanced chronic kidney disease (stages 4 and 5) (n=52). Discontinuation of ACEi/ARB vs. Baseline (before discontinuation) was evaluated on Estimated glomerular filtration rate (eGFR) (p=0.0001). Discontinuation of ACEi/ARB in patients with advanced CKD significantly increased eGFR from 16.38 to 26.6 ml/min/1.73 m2 at 12 months (p=0.0001), delaying the onset of renal replacement therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: